KR102367941B1 - 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2 - Google Patents

락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2 Download PDF

Info

Publication number
KR102367941B1
KR102367941B1 KR1020167003267A KR20167003267A KR102367941B1 KR 102367941 B1 KR102367941 B1 KR 102367941B1 KR 1020167003267 A KR1020167003267 A KR 1020167003267A KR 20167003267 A KR20167003267 A KR 20167003267A KR 102367941 B1 KR102367941 B1 KR 102367941B1
Authority
KR
South Korea
Prior art keywords
casein
beta
milk
lactose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167003267A
Other languages
English (en)
Korean (ko)
Other versions
KR20160030974A (ko
Inventor
앤드류 존 클라크
말라브 수친 트리베디
Original Assignee
디 에이2 밀크 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52280344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102367941(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 디 에이2 밀크 컴퍼니 리미티드 filed Critical 디 에이2 밀크 컴퍼니 리미티드
Priority to KR1020207019514A priority Critical patent/KR102291660B1/ko
Publication of KR20160030974A publication Critical patent/KR20160030974A/ko
Application granted granted Critical
Publication of KR102367941B1 publication Critical patent/KR102367941B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Peptides Or Proteins (AREA)
KR1020167003267A 2013-07-12 2014-07-10 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2 Active KR102367941B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207019514A KR102291660B1 (ko) 2013-07-12 2014-07-10 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845480P 2013-07-12 2013-07-12
US61/845,480 2013-07-12
PCT/NZ2014/000141 WO2015005804A1 (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207019514A Division KR102291660B1 (ko) 2013-07-12 2014-07-10 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2

Publications (2)

Publication Number Publication Date
KR20160030974A KR20160030974A (ko) 2016-03-21
KR102367941B1 true KR102367941B1 (ko) 2022-02-24

Family

ID=52280344

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167003267A Active KR102367941B1 (ko) 2013-07-12 2014-07-10 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2
KR1020207019514A Active KR102291660B1 (ko) 2013-07-12 2014-07-10 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207019514A Active KR102291660B1 (ko) 2013-07-12 2014-07-10 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2

Country Status (20)

Country Link
US (3) US20160136238A1 (https=)
EP (2) EP3542805A1 (https=)
JP (2) JP6436592B2 (https=)
KR (2) KR102367941B1 (https=)
CN (3) CN110800803A (https=)
AU (2) AU2014287862B2 (https=)
BR (1) BR112016000612B8 (https=)
CA (2) CA3214545A1 (https=)
CL (1) CL2016000064A1 (https=)
DK (1) DK3019180T3 (https=)
ES (1) ES2743194T3 (https=)
IL (2) IL243366B (https=)
MX (2) MX368912B (https=)
MY (2) MY190309A (https=)
NZ (2) NZ754642A (https=)
PH (2) PH12016500032B1 (https=)
RU (1) RU2671562C2 (https=)
SG (2) SG10201710237PA (https=)
WO (1) WO2015005804A1 (https=)
ZA (1) ZA201600007B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
JP7137745B2 (ja) * 2015-05-22 2022-09-15 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼインａ２および抗酸化能
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
WO2017171563A1 (en) 2016-03-30 2017-10-05 The A2 Milk Company Limited Beta-caseins and cognitive function
JP6873234B2 (ja) * 2016-09-30 2021-05-19 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および腸微生物叢
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
EP4377480A4 (en) * 2021-07-30 2025-09-24 Active Genomes Expressed Diagnostics Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND LIVER DISEASE
AU2024262008A1 (en) * 2023-04-25 2025-11-13 The A2 Milk Company Limited Beta-caseins in infant milk formula and use for reducing crying episodes in infants
WO2024225919A1 (en) * 2023-04-25 2024-10-31 The A2 Milk Company Limited Beta-caseins in infant milk formula and use for reducing regurgitation episodes in infants
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用
CN117322466A (zh) * 2023-11-02 2024-01-02 光明乳业股份有限公司 一种新型婴幼儿食用的发酵乳及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000047A1 (en) 1999-06-29 2001-01-04 The New Zealand Milk Institute Limited Prophylactic dietary supplement based on milk
WO2004030690A1 (en) 2002-10-04 2004-04-15 A2 Corporation Limited THERAPEUTIC USES OF β-CASEIN A2 AND DIETARY SUPPLEMENT CONTAINING β-CASEIN A2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
WO1996036239A1 (en) 1995-05-16 1996-11-21 Corran Norman Stuart Mclachlan Food product and process
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
DK1663298T3 (da) * 2003-09-23 2019-10-14 Dsm Ip Assets Bv Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
CN1899054A (zh) * 2006-07-17 2007-01-24 颜贻谦 去糖牛奶的制作方法
JP2012522505A (ja) * 2009-04-03 2012-09-27 ネステク ソシエテ アノニム ミルク様飲料
AU2010238184B2 (en) * 2009-04-15 2014-09-04 Glanbia Nutritionals (Ireland) Limited A reduced lactose milk product and a process for the preparation thereof
DE102010009582A1 (de) * 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
MX389785B (es) * 2011-07-26 2025-03-18 Nucitec Sa De Cv Composicion nutrimental para niños que presentan reflujo, colico y/o estreñimiento.
CN103315063A (zh) * 2012-03-19 2013-09-25 基斯有限公司 可预防疾病的婴儿配方奶粉
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000047A1 (en) 1999-06-29 2001-01-04 The New Zealand Milk Institute Limited Prophylactic dietary supplement based on milk
WO2004030690A1 (en) 2002-10-04 2004-04-15 A2 Corporation Limited THERAPEUTIC USES OF β-CASEIN A2 AND DIETARY SUPPLEMENT CONTAINING β-CASEIN A2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, Vol. 46, No. 1, pp. 93-100 (2006)
MUTATION RESEARCH, Vol. 690, No. 1-2, pp. 64-70 (2010)

Also Published As

Publication number Publication date
US20220175882A1 (en) 2022-06-09
KR102291660B1 (ko) 2021-08-19
CA2917492C (en) 2023-11-14
IL261143B (en) 2021-02-28
PH12016500032B1 (en) 2019-10-25
IL261143A (en) 2018-10-31
AU2014287862B2 (en) 2019-07-11
SG10201710237PA (en) 2018-01-30
HK1223846A1 (en) 2017-08-11
KR20200085375A (ko) 2020-07-14
RU2018131604A3 (https=) 2022-04-19
JP6436592B2 (ja) 2018-12-12
MY172939A (en) 2019-12-16
RU2015156804A3 (https=) 2018-05-31
ZA201600007B (en) 2017-11-29
AU2019203684B2 (en) 2021-08-05
ES2743194T3 (es) 2020-02-18
IL243366B (en) 2018-11-29
BR112016000612B8 (pt) 2022-02-22
SG11201510707YA (en) 2016-01-28
NZ715985A (en) 2022-09-30
AU2019203684A1 (en) 2019-06-20
AU2014287862A1 (en) 2016-02-11
CN114832092A (zh) 2022-08-02
EP3542805A1 (en) 2019-09-25
PH12019550112A1 (en) 2020-09-14
CN105431156A (zh) 2016-03-23
NZ754642A (en) 2022-09-30
PH12016500032A1 (en) 2016-03-28
MX2019012446A (es) 2020-02-03
EP3019180B1 (en) 2019-05-29
RU2671562C2 (ru) 2018-11-02
WO2015005804A1 (en) 2015-01-15
BR112016000612A2 (https=) 2017-07-25
MX368912B (es) 2019-10-21
MY190309A (en) 2022-04-13
MX2016000308A (es) 2016-11-14
BR112016000612B1 (pt) 2021-11-03
EP3019180A4 (en) 2017-03-08
CL2016000064A1 (es) 2016-12-16
DK3019180T3 (da) 2019-08-26
RU2018131604A (ru) 2018-11-20
JP2016523958A (ja) 2016-08-12
CA2917492A1 (en) 2015-01-15
JP6990154B2 (ja) 2022-01-12
RU2015156804A (ru) 2017-08-17
CN110800803A (zh) 2020-02-18
KR20160030974A (ko) 2016-03-21
US20160136238A1 (en) 2016-05-19
CA3214545A1 (en) 2015-01-15
MX394585B (es) 2025-03-04
US20200147173A1 (en) 2020-05-14
JP2018203753A (ja) 2018-12-27
EP3019180A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
KR102367941B1 (ko) 락토스 불내증의 증상을 감소시키거나 예방하는 베타-카세인 a2
KR102402455B1 (ko) 베타­카세인 ａ2 및 창자의 염증 예방
RU2698794C2 (ru) Бета-казеин а2 и уровень глюкозы в крови
Yasuda et al. Supplemental dietary inulin influences expression of iron and inflammation related genes in young pigs
Huang et al. Swainsonine differentially affects steroidogenesis and viability in caprine luteal cells in vitro
RU2791693C2 (ru) Бета-казеин а2 и уменьшение или предотвращение симптомов непереносимости лактозы
HK40013850A (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
HK1223846B (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
RU2784851C2 (ru) Бета-казеин а2 и предотвращение воспаления кишечника
Zhang et al. vesicles mitigate mammary gland ferroptosis via the gut-mammary gland axis
HK40013851A (en) Beta-casein a2 and prevention of inflammation of the bowel
HK1222362B (en) Composition comprising beta-casein a2 for use in the prevention of inflammation of the bowel

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190604

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200619

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200706

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201228

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20200619

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210527

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200706

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190617

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190604

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210910

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220209

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20211103

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210830

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210527

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200706

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190617

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190604

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20240723

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20220222

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20240723

Appeal identifier: 2024100002192

PR1001 Payment of annual fee

Payment date: 20250211

Start annual number: 4

End annual number: 4

J301 Trial decision

Free format text: TRIAL NUMBER: 2024100002192; TRIAL DECISION FOR INVALIDATION REQUESTED 20240723

Effective date: 20250219

PJ1301 Trial decision

Patent event code: PJ13011S05D

Patent event date: 20250219

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20240723

Decision date: 20250219

Appeal identifier: 2024100002192